These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
263 related articles for article (PubMed ID: 12458143)
1. In vitro activity of moxifloxacin, levofloxacin, gatifloxacin and linezolid against Mycobacterium tuberculosis. Rodríguez JC; Ruiz M; López M; Royo G Int J Antimicrob Agents; 2002 Dec; 20(6):464-7. PubMed ID: 12458143 [TBL] [Abstract][Full Text] [Related]
2. In vitro activity of new fluoroquinolones and linezolid against non-tuberculous mycobacteria. Rodriguez Díaz JC; López M; Ruiz M; Royo G Int J Antimicrob Agents; 2003 Jun; 21(6):585-8. PubMed ID: 12791475 [TBL] [Abstract][Full Text] [Related]
3. Comparative in vitro activity of penicillin G, levofloxacin, moxifloxacin, telithromycin, pristinamycin, quinupristin-dalfopristin and linezolid against ofloxacin-intermediate and -resistant Streptococcus pneumoniae. Frédénucci I; Chomarat M; Bercion R; Carricajo A; Celard M; Croizé J; Delubac F; Fèvre D; Fuhrmann C; Helfre M; Letouzey MN; Lelièvre H; Mandjee A; Marthelet P; Meley R; Perrier-Gros-Claude JD; Ros A; Roure C; Smati S; Thierry J; Tous J Clin Microbiol Infect; 2002 Oct; 8(10):680-3. PubMed ID: 12390289 [TBL] [Abstract][Full Text] [Related]
4. Ciprofloxacin- and methicillin-resistant staphylococcus aureus susceptible to moxifloxacin, levofloxacin, teicoplanin, vancomycin and linezolid. Presterl E; Mueller-Uri P; Grisold A; Georgopoulos A; Graninger W Eur J Clin Microbiol Infect Dis; 2001 Jul; 20(7):486-9. PubMed ID: 11561805 [TBL] [Abstract][Full Text] [Related]
5. In vitro activity of four fluoroquinolones against Mycobacterium tuberculosis. Rodríguez JC; Ruiz M; Climent A; Royo G Int J Antimicrob Agents; 2001 Mar; 17(3):229-31. PubMed ID: 11282270 [TBL] [Abstract][Full Text] [Related]
6. Importance of the efflux pump systems in the resistance of Mycobacterium tuberculosis to fluoroquinolones and linezolid. Escribano I; Rodríguez JC; Llorca B; García-Pachon E; Ruiz M; Royo G Chemotherapy; 2007; 53(6):397-401. PubMed ID: 17934259 [TBL] [Abstract][Full Text] [Related]
7. Mutant prevention concentration: comparison of fluoroquinolones and linezolid with Mycobacterium tuberculosis. Rodríguez JC; Cebrián L; López M; Ruiz M; Jiménez I; Royo G J Antimicrob Chemother; 2004 Mar; 53(3):441-4. PubMed ID: 14963069 [TBL] [Abstract][Full Text] [Related]
8. Synergic activity of fluoroquinolones and linezolid against Mycobacterium tuberculosis. Rodriguez Díaz JC; Ruiz M; López M; Royo G Int J Antimicrob Agents; 2003 Apr; 21(4):354-6. PubMed ID: 12672583 [TBL] [Abstract][Full Text] [Related]
9. [In vitro activity of linezolid, moxifloxacin, levofloxacin, clindamycin and rifampin, alone and in combination, against Staphylococcus aureus and Staphylococcus epidermidis]. Soriano A; Jurado A; Marco F; Almela M; Ortega M; Mensa J Rev Esp Quimioter; 2005 Jun; 18(2):168-72. PubMed ID: 16130039 [TBL] [Abstract][Full Text] [Related]
10. Action of fluoroquinolones and Linezolid on logarithmic- and stationary-phase culture of Mycobacterium tuberculosis. García-Tapia A; Rodríguez JC; Ruiz M; Royo G Chemotherapy; 2004 Nov; 50(5):211-3. PubMed ID: 15523179 [TBL] [Abstract][Full Text] [Related]
11. Single and multi-step resistance selection study in Streptococcus pneumoniae comparing ceftriaxone with levofloxacin, gatifloxacin and moxifloxacin. Browne FA; Clark C; Bozdogan B; Dewasse BE; Jacobs MR; Appelbaum PC Int J Antimicrob Agents; 2002 Aug; 20(2):93-9. PubMed ID: 12297357 [TBL] [Abstract][Full Text] [Related]
12. Population pharmacokinetics of levofloxacin, gatifloxacin, and moxifloxacin in adults with pulmonary tuberculosis. Peloquin CA; Hadad DJ; Molino LP; Palaci M; Boom WH; Dietze R; Johnson JL Antimicrob Agents Chemother; 2008 Mar; 52(3):852-7. PubMed ID: 18070980 [TBL] [Abstract][Full Text] [Related]
13. Analysis of mutations in the gyrA and gyrB genes and their association with the resistance of Mycobacterium tuberculosis to levofloxacin, moxifloxacin and gatifloxacin. Nosova EY; Bukatina AA; Isaeva YD; Makarova MV; Galkina KY; Moroz AM J Med Microbiol; 2013 Jan; 62(Pt 1):108-113. PubMed ID: 23019190 [TBL] [Abstract][Full Text] [Related]
14. E test susceptibility testing of nosocomial Clostridium difficile isolates against metronidazole, vancomycin, fusidic acid and the novel agents moxifloxacin, gatifloxacin, and linezolid. Leroi MJ; Siarakas S; Gottlieb T Eur J Clin Microbiol Infect Dis; 2002 Jan; 21(1):72-4. PubMed ID: 11913510 [No Abstract] [Full Text] [Related]
15. Gatifloxacin and moxifloxacin: an in vitro susceptibility comparison to levofloxacin, ciprofloxacin, and ofloxacin using bacterial keratitis isolates. Kowalski RP; Dhaliwal DK; Karenchak LM; Romanowski EG; Mah FS; Ritterband DC; Gordon YJ Am J Ophthalmol; 2003 Sep; 136(3):500-5. PubMed ID: 12967804 [TBL] [Abstract][Full Text] [Related]
16. Comparative in vitro activity of gatifloxacin, grepafloxacin, levofloxacin, moxifloxacin and trovafloxacin against 4151 Gram-negative and Gram-positive organisms. Blondeau JM; Laskowski R; Bjarnason J; Stewart C Int J Antimicrob Agents; 2000 Feb; 14(1):45-50. PubMed ID: 10717500 [TBL] [Abstract][Full Text] [Related]
17. Comparative activities of ciprofloxacin, clinafloxacin, gatifloxacin, gemifloxacin, levofloxacin, moxifloxacin, and trovafloxacin against epidemiologically defined Acinetobacter baumannii strains. Heinemann B; Wisplinghoff H; Edmond M; Seifert H Antimicrob Agents Chemother; 2000 Aug; 44(8):2211-3. PubMed ID: 10898706 [TBL] [Abstract][Full Text] [Related]
18. In vitro activity of fluoroquinolones against Mycobacterium tuberculosis. Sulochana S; Rahman F; Paramasivan CN J Chemother; 2005 Apr; 17(2):169-73. PubMed ID: 15920901 [TBL] [Abstract][Full Text] [Related]
19. Benzalkonium chloride enhances antibacterial activity of gatifloxacin and reduces its propensity to select for fluoroquinolone-resistant strains. Hesje CK; Borsos SD; Blondeau JM J Ocul Pharmacol Ther; 2009 Aug; 25(4):329-34. PubMed ID: 19650708 [TBL] [Abstract][Full Text] [Related]
20. In vitro activity of linezolid, clarithromycin and moxifloxacin against clinical isolates of Mycobacterium kansasii. Guna R; Muñoz C; Domínguez V; García-García A; Gálvez J; de Julián-Ortiz JV; Borrás R J Antimicrob Chemother; 2005 Jun; 55(6):950-3. PubMed ID: 15824090 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]